About ViaLase
ViaLase is a Healthcare company based in Newport Beach (United States) founded in 2018. It operates as an image-guided femtosecond laser devices for glaucoma treatments are developed. ViaLase has raised $45.18 million across 2 funding rounds from investors including Falcon-Vision, Venture Investors and Arboretum Ventures. ViaLase offers products and services including ViaLase Laser System and FLigHT Procedure. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is ViaLase, Inc. Its competitors include BELKIN Vision, ELIOS Vision, Radiance Therapeutics and EyeLight; 2 of its 4 listed competitors have raised funding.
Company details
The company was founded in 2018 and is headquartered in Newport Beach, United States. Operations center on the medical device sector, specifically ophthalmology, where image-guided femtosecond laser systems are developed for glaucoma procedures. These devices incorporate imaging technology to assist surgical interventions. Focus remains on advancing treatments for glaucoma patients through precise, non-invasive methods in a clinical setting.
- Headquarters Newport Beach, United States
- SectorsHealthcare
- Website vialase.com
- Social LinkedIn Instagram
- Legal Name Vialase, Inc.
- Total Equity Funding$45.18M (USD)
in 2 rounds
- Latest Funding Round$45.18M (USD), Series C
Mar 2024
- InvestorsFalcon-Vision
& 2 more
Products & Services of ViaLase
ViaLase offers a comprehensive portfolio of products and services, including ViaLase Laser System and FLigHT Procedure.
Noninvasive laser for creating apertures in trabecular meshwork to treat glaucoma.
Noninvasive glaucoma intervention without surgery or incisions.
Funding Insights of ViaLase
ViaLase has successfully raised a total of $45.18M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $45.18 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45.18M
- Total Rounds 2
- Last Round Series C — $45.18M
- First Round $3.5M
(Jan 2024)
- Investors Count 3
All 2 funding rounds of ViaLase with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $45.18M | Series C | – | Venture Investors, Arboretum Ventures | – |
| Jan 2024 | $3.5M | Debt – Conventional | – | – | – |
3 investors in total: 3 institutional.
Investors in ViaLase
ViaLase has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Falcon-Vision, Venture Investors and Arboretum Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | – | ventureinvestors.com | Madison, United States | |
Healthcare venture capital investments are made by Arboretum Ventures. | – | arboretumvc.com | Ann Arbor, United States | |
Industrial machinery is manufactured and distributed by Falcon-Vision since 1996. | 1996 | falcon-vision.com | Budapest, Hungary |
Investor details for ViaLase
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ViaLase
8 people are tracked at ViaLase (7 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Christina Wardell | Director of Service Operations | Leadership |
Pete England | Chief Commercial Officer | Leadership |
Tibor Juhasz | Founder and CEO | Leadership |
Kristy Miller | Vice President, Head Of People | Leadership |
Carlos Suarez | Vp. Regulatory Affairs & Quality Assurance | Leadership |
Brendan O Herlihy | Vice President Global Commercial Operations | Leadership |
Hadi Srass | Chief Operating Officer | Leadership |
Eberto Parrilla | Logistics & Facilities Manager | Team |
Complete people profiles for ViaLase
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ViaLase
3 dated milestones of ViaLase across 6 years, from founding to its latest funding, stage changes and deals.
- Founded ViaLase is founded.
- Funding First funding round of $3.5M.
- Funding Latest funding round, Series C, of $45.2M.
Competitors of ViaLase
ViaLase has 4 listed competitors in our database, 2 of them funded. They include BELKIN Vision, ELIOS Vision, Radiance Therapeutics and EyeLight, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| belkin-vision.com | 2013 | Yavne, Israel | $14.75M | – | Laser device for glaucoma treatment developed by BELKIN Vision. | |
| eliosvision.com | 2019 | Los Angeles, United States | – | – | Excimer laser technology is applied to develop glaucoma therapy devices. | |
| radiancetherapeutics.com | 2018 | Oro Valley, United States | $14M | – | Beta ophthalmic applicator for glaucoma surgery is developed. | |
| eyelight.us | 2004 | Carlsbad, United States | – | – | Develops patented treatment methods for glaucoma. |
Detailed competitors of ViaLase
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ViaLase
The website of ViaLase (vialase.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 20.2% vs previous month
Top companies in Ophthalmology
10 companies that operate in the same segment as ViaLase (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vialase
Complete news archive for ViaLase
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViaLase
ViaLase was founded in 2018 and raised its 1st funding round 6 years after it was founded.
ViaLase is headquartered in Newport Beach, United States. It is registered at Newport Beach, California, United States.
ViaLase is a funded company, having raised a total of $45.18M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $3.5M, raised on Jan 2024.
The company was founded in 2018 and is headquartered in Newport Beach, United States. Operations center on the medical device sector, specifically ophthalmology, where image-guided femtosecond laser systems are developed for glaucoma procedures. These devices incorporate imaging technology to assist surgical interventions. Focus remains on advancing treatments for glaucoma patients through precise, non-invasive methods in a clinical setting.
ViaLase's top competitors include ELIOS Vision, BELKIN Vision and Radiance Therapeutics.
ViaLase offers ViaLase Laser System and FLigHT Procedure.
ViaLase has 3 investors. Key investors include Falcon-Vision, Venture Investors, and Arboretum Ventures.
ViaLase operates through Vialase, Inc..